FDA approves Auvelity for agitation

Alzheimer’s agitation is one of the hardest parts of dementia care — not because it is rare, but because it can turn fear, pacing, yelling, or aggression into a daily crisis for families and staff. The big news is that the FDA, on April 30, 2026, approved Auvelity for agitation associated with dementia due to Alzheimer’s disease in adults. That gives doctors a new on-label option for a problem that has mostly been managed with imperfect workarounds. It also makes Auvelity the first FDA-approved treatment for this condition that is not an antipsychotic. (fda.gov) ### What exactly got approved? Auvelity is a fixed-dose pill that combines dextromethorphan and bupropion in an extended-release tablet. Until now, it was approved for major depressive disorder in adults. The new FDA action expands its use to agitation linked to Alzheimer’s dementia — so this is a label expansion, not a brand-new drug launch. (fda.gov) ### Why is agitation such a big deal? Agitation in Alzheimer’s is more than “restlessness.” It can mean excessive motor activity, verbal outbursts, or physical aggression. That can wreck sleep, strain caregivers, speed institutional placement, and make ordinary care — bathing, meals, clinic visits, even post-o(fda.gov)0% of people living with Alzheimer’s disease. (fda.gov) ### Why is the “non-antipsychotic” part the real story? Because the field has leaned for years on off-label antipsychotics, and those drugs come with baggage in dementia. The FDA described Auvelity as the first approved treatment for this condition that is not an antipsychotic. That matters because antipsychot(fda.gov)now well. Basically, this approval opens a different lane. (fda.gov) ### How does Auvelity work? The drug combines dextromethorphan — which acts as an NMDA receptor antagonist and sigma-1 receptor agonist — with bupropion, which also helps raise dextromethorphan exposure by inhibiting CYP2D6. Axsome pitches the combo as a first-in-class approach for agitation in Alzheimer’s dis(fda.gov)meone with an antipsychotic. (accessdata.fda.gov) ### What convinced the FDA? Two randomized studies did the work. In one five-week placebo-controlled trial, Auvelity beat placebo on the Cohen-Mansfield Agitation Inventory, a caregiver-rated measure of agitated behavior. In the second study, a randomized withdrawal trial, patients who had responded to Auvelity were either kept on the drug or switched (accessdata.fda.gov)ed on ClinicalTrials.gov says that withdrawal phase could run up to 24 weeks. (fda.gov) ### What are the catches? This is not a side-effect-free dementia drug. The FDA lists common adverse effects including dizziness, upset stomach, headache, diarrhea, drowsiness, dry mouth, sexual dysfunction, and excessive sweating. Auvelity also keeps its boxed warning about suicidal thoughts and behaviors in (fda.gov)ic reactions. Most Alzheimer’s patients are older, but the warning architecture still matters because the product is an antidepressant combination. (fda.gov) ### What changes for care right now? The immediate change is simple — doctors now have an FDA-approved, oral, non-antipsychotic option for Alzheimer’s-related agitation instead of relying so heavily on off-label prescribing. That will not replace behavioral care, environmental changes, or careful assessment for pain, infection, or delirium. But it does give clinicians and caregivers another tool when agitation is persistent and disruptive. (fda.gov) ### Bottom line This approval is really about a gap finally narrowing. Alzheimer’s agitation has been common, dangerous, and hard to treat without ugly tradeoffs. Auvelity does not solve that whole problem — but it gives the field a new, on-label option in a place where choices have been thin for a long time. (fda.gov)